EU Approves Dapagliflozin for Kidney Disease, Regardless of Diabetes EU Approves Dapagliflozin for Kidney Disease, Regardless of Diabetes

The decision rested on results from the DAPA-CKD pivotal trial and followed US FDA approval last April for adults with chronic kidney disease regardless of whether they also have type 2 diabetes.International Approvals
Source: Medscape Transplantation Headlines - Category: Transplant Surgery Tags: Diabetes & Endocrinology News Alert Source Type: news